Difei Yang
Stock Analyst at Mizuho
(2.18)
# 2,763
Out of 4,945 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $3.29 | -39.21% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $11.59 | +1,625.63% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.94 | +1,858.76% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $9.48 | +7,547.68% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $15.78 | +229.53% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $20.30 | +688.18% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $7.30 | +91.78% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $26.69 | +1,867.03% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.15 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $9.07 | +208.71% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.35 | +1,974.07% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $3.29
Upside: -39.21%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $11.59
Upside: +1,625.63%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.94
Upside: +1,858.76%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $9.48
Upside: +7,547.68%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $15.78
Upside: +229.53%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $20.30
Upside: +688.18%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $7.30
Upside: +91.78%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $26.69
Upside: +1,867.03%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.15
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $9.07
Upside: +208.71%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.35
Upside: +1,974.07%